Antibacterial Antibiotics and Bacterial Probiotics: is it Possible to Combine the Incompatible
Abstract
The purpose of the study was to analyze validity and effectiveness of simultaneous application of bacterial probiotics and antibacterial antibiotics during antimicrobial therapy. Materials and methods. The review includes materials of foreign and domestic researchers published in modern periodical and monographic literature. Results. The conceptual material of the main terms and definitions of «ideal» antibiotics and probiotics is presented. The dominant role of bacterial probiotics in the group of medical probiotics in the Russian pharmaceutical market was established. A comparative assessment of the data on the passportization, identification, and sensitivity to antibiotics of a number of commercial probiotic cultures was carried out. The article considers theoretical and practical joint use of antibiotics, probiotics, and metabiotics during antimicrobial therapy. Conclusion. The current practice ofjoint use of probiotics and antibiotics in the process of antimicrobial therapy is extremely limited and indicates the presence of serious circumstances that reduce the effectiveness of probiotic therapy. One of the directions that exclude this situation is the use of metabiotics in the form of medications.
About the Author
V. I. Kocherovets
I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Кочеровец В.И. Хилак форте: современная модель метабиотика с биотерапевтической активностью. Монография по продукту. - М.: ООО «Прайм-Медиа», 2018. - 72 с.
2. Юрятин A.A. Легко ли ужиться антибиотикам и пробиотикам в кишечнике? Спросим у фармакокинетики. Практика педиатра. - 2017. - № 1. - С. 58-64.
3. Кира Е.Ф. Пробиотики в восстановлении микробиоценоза влагалища. Акушерство и гинекология. - 2017. - № 5. - С. 32-8. D0I:10.18565/aig.2017.5.32-8
4. Государственный реестр лекарственных средств 2018. http//grls.rosminzdrav.ru. Дата обращения 05.03.2018.
5. Anderson D., ed. Dorland's Illustrated Medical Dictionary. 30th ed. Saunders; 2003.
6. Bhattacharjee M.K., ed. Chemistry of Antibiotics and Related Drugs. Springer; 2016: 219.
7. Technavio. Global Antibiotics Market 2014-2018. Report. www.tech-navio.com/report/global-antibiotics-market-2014-2018
8. Guarner F., Schaafsma G.J. Probiotics. Int J Food Microbiol. 1998; 39 (3): 237-238.
9. FAO/WHO working group. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, Argentina; 2001.
10. Отраслевой стандарт введен в действие ОСТ 91500.11.0004-2003. Приказ Минздрава России от 9 июня 2003 г. № 231 «Об утверждении отраслевого стандарта «Протокол ведения больных. Дисбактериоз кишечника».
11. Kalliomäki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357 (9262): 1076-1079.
12. Govender M., Choonara Y.E., Kumar P., du Toit L.C., van Vuuren S., Pillay V. A review of the advancements in probiotic delivery: Conventional vs. non-conventional formulations for intestinal flora supplementation. AAPS Pharm Sci Tech 2014; 15 (1): 29-43.
13. Penner R., Fedorak R.N., Madsen K.L. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr Opin Pharmacol 2005; 5 (6): 596-603.
14. Douillard F.P., de Vos W.M. Functional genomics of lactic acid bacteria: from food to health. Microb Cell Fact 2014; 13: Suppl 1: S8.
15. Besselink M.G., van Santvoort H.C., Buskens E. et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371 (9613): 651-659.
16. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324 (7350): 1361.
17. Salminen S., von Wright A. Probiotics: safety and efficacy. In: Lahtinen S., Ouwehand A.C., Salminen S., von Wright, eds. Lactic Acid Bacteria: Microbiological and Functional Aspects. 4th ed. Boca Raton, FL: Taylor & Francis Group; 2012; 689-704.
18. Sommer M.O.A., Dantas G., Church G.M. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science. 2009; 325 (5944): 1128-1131.
19. Davies J. Antibiotic resistance in and from nature. Microbiol Spectrum 2013; 1(1): OH-0005-2012. doi:10.1128/microbiolspec.OH-0005-2012.
20. Sommer M.O., Church G.M., Dantas G. The human microbiome harbors a diverse reservoir of antibiotic resistance genes. Virulence 2010; 1 (4): 299-303.
21. Demain A.L., Lancini G. Bacterial pharmaceutical products. In: Dworkin M. et al., eds. The Prokaryotes. A Handbook of the Biology of Bacteria. 3rd ed. Singapore: Springer; 2006; 810-831.
22. Bell B.G., Schellevis F., Stobberingh E., Goossens H., Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 2014; 14: 13.
23. Савичева A.M., Рыбина Е.В. Исследование in vitro роста, размножения, антибиотикорезистентности, конкурентных взаимоотноше ний штамма Lactobacillus casei rhamnosus. Акушерство и гинекология. - 2014. - № 7. - С. 79-83
24. Кочеровец В.И. Ещё раз об известном. Акушерство и гинекология. 2009; 3: 66-68
25. Кочеровец В.И. Глево: современная таблетированная форма левофлоксацина системного действия: монография по продукту. - М. - СПб.: Полифорум, 2015. - 79 с
26. Кочеровец В.И., Бунятян Н.Д. Современные лекарственные препараты левофлоксацина в клинической практике: учебное пособие. - М. - СПб.: Полифорум, 2016. - C. 107
27. Сухорукова М.В., Тимохова А.В., Эйдельштейн М.В., Козлов Р.С. Чувствительность к антибиотикам штаммов бактерий, входящих в состав пробиотика «Линекс». Клин микробиол и антимикроб химиотер. - 2012. - Т. 14. - № 3. - С. 248-251
28. Meropol S.B., Localio A.R., Metlay J.P. Risks and benefits associated with antibiotic use for acute respiratory infections: a cohort study. Ann Fam Med 2013; 11 (2): 165-172.
29. Данные IQVIA™, 2018.
30. Инструкция Амоксил США. https://www.accessdata.fda.gov/drugsatf-da_docs/label/2011/050542s026s027s028,050754s013s014s017,050760s0 12s013s015,050761s012s013s015lbl.pdf / Instrukciya Amoksil SSHA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050542s026 s027s028,050754s013s014s017,050760s012s013s015,050761s012s013s015 lbl.pdf [in Russian]
31. Babickova J., Gardlik R. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World J Gastroenterol 2015; 21 (40): 11321-1130.
32. Altuntas S., Korukluoglu M., Altuntas V. Probiotic Escherichia coli strain Nissle 1917. Pamukkale Univ Muh Bilim Derg 2017; 23 (7): 933-940. doi: 10.5505/pajes.2017.98475.
33. Sonnenborn U., Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917 - features of a versatile probiotic. Microb Ecol Health Dis 2009; 21 (3-4): 122-158.
34. Vos P., Garrity G., Jones D., eds. Bergey's Manual of Systematic Bacteriology. Vol. 3: The Firmicutes. 2nd ed. New York, NY: Springer-Verlag; 2009; 1450.
35. Versalovic J., Carroll K.C., Funke G., Jorgensen J.H., Landry M.L., Warnock D.W. Manual of Clinical Microbiology. Systems for Detection and Identification of Bacteria and Yeasts. Vol. 1. ASM Press. 2011.
36. Mitsuoka T. The human gastrointestinal tract. In: Wood BJB. The Lactic Acid Bacteria. Vol. 1. Boston, MA: Springer; 1992; 69-114.
37. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol 2001; 2 (2): 43-53.
38. Червинец Ю.В., Червинец В.М., Миронов А.Ю. Симбиотические взаимоотношения лактобацилл и микроорганизмов желудочно-кишечного тракта. Тверь: Ред.из. центр Твер.гос.мед.ун-та, 2016. - 214 с.
39. Ботина С.Г. Реклассификация отечественных производственных культур бактерий рода Lactobacillus и сравнительная характеристика их технологических свойств. Материалы II Международной научно-практической конференции «Актуальные проблемы биологии, нанотехнологий и медицины» Ростов-на-Дону, сентябрь 2009. - С. 10
40. Winn W.C. Koneman's Color Atlas and Textbook of Diagnostic Microbiology. Lippincott Williams & Wilkins; 2017.
41. Brook I., Wexler H.M., Goldstein E.J. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013; 26 (3): 526-546.
42. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100 (ISBN 1-56238-838-X [Print]; ISBN 1-56238-839-8 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.
43. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1. 15 May 2018.
44. Определение чувствительности микроорганизмов к антибактериальным препаратам: Методические указания МУК 4.2.1890-04. Клин микробиол антимикроб химиотер. - 2004. - Т. 6. - № 4. - С. 306-359
Review
For citations:
Kocherovets V.I. Antibacterial Antibiotics and Bacterial Probiotics: is it Possible to Combine the Incompatible. Antibiot Khimioter = Antibiotics and Chemotherapy. 2018;63(5-6):34-42. (In Russ.)
Views:
621
Email this article 